• Home
  •  / Takeda Pharmaceutical

Takeda Pharmaceutical

OverviewSuggest Edit

Takeda Pharmaceutical is a biopharmaceutical company. It develops and markets pharmaceutical products in gastroenterology, rare diseases including rare metabolic, rare hematology and heredity angioedema, oncology, neuroscience, as well as plasma-derived therapies and vaccines. Takeda's key products in its key business areas include the following 14 global brands: ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/ADYNOVI, TAKHZYRO, ELAPRASE, VPRIV, GAMMAGARD LIQUID/KIOVIG, HYQVIA, CUVITRU, ALBUMIN/FLEXBUMIN, NINLARO, and ALUNBRIG.

TypePublic
Founded1781
HQTokyo, JPMap
Websitetakeda.com
Overall CultureA+More
View Jobs (1,679)

Recent NewsAll News

Latest Updates

Employees (est.) (Mar 2020)47,495(-4%)
Job Openings1,679
Revenue (FY, 2020)¥3.3 T(+57%)
Share Price (Jul 2021)¥3.7 K
Cybersecurity ratingCMore

Key People/Management at Takeda Pharmaceutical

Andrew S. Plump

Andrew S. Plump

Director President, Research & Development
Masato Iwasaki

Masato Iwasaki

Director President, Japan Pharma Business Unit
Christophe Weber

Christophe Weber

Representative Director, President & CEO
Costa Saroukos

Costa Saroukos

Director, Chief Financial Officer
Marcello Agosti

Marcello Agosti

Global Business Development Officer
Teresa Bitetti

Teresa Bitetti

President, Global Oncology Business Unit
Show more

Takeda Pharmaceutical Office Locations

Takeda Pharmaceutical has offices in Tokyo, Fujisawa, Fukuchiyama, Hikari and in 47 other locations
Tokyo, JP (HQ)
1-1, Nihonbashi-Honcho 2-chome, Chuo-ku
Fujisawa, JP
26-1, Muraoka-Higashi 2-chome
Fukuchiyama, JP
2-21 Osadano
Hikari, JP
4720, Takeda , Mitsui
Osaka, JP
1-1, Doshomachi 4-chome, Chuo-ku
Osaka, JP
17-85, Jusohonmachi 2-chome, Yodogawa-ku
Show all (52)

Takeda Pharmaceutical Financials and Metrics

Takeda Pharmaceutical Revenue

Embed Graph
View revenue for all periods
Takeda Pharmaceutical's revenue was reported to be ¥3.29 t in FY, 2020 which is a 56.9% increase from the previous period.
JPY

Revenue (H1, 2021)

1.6t

Gross profit (H1, 2021)

1.1t

Gross profit margin (H1, 2021), %

69.3%

Net income (H1, 2021)

86.6b

EBIT (H1, 2021)

215.6b

Market capitalization (21-Jul-2021)

5.8t

Closing stock price (21-Jul-2021)

3.7k

Cash (30-Sept-2020)

630.9b

EV

10.1t
Takeda Pharmaceutical's current market capitalization is ¥5.8 t.
Annual
JPYFY, 2018FY, 2019FY, 2020

Revenue

1.8t2.1t3.3t

Revenue growth, %

18%57%

Cost of goods sold

495.9b659.7b1.1t

Gross profit

1.3t1.4t2.2t
Half Year
JPYH1, 2019H1, 2020H1, 2021

Revenue

880.6b1.7t1.6t

Cost of goods sold

231.3b572.3b487.7b

Gross profit

649.3b1.1t1.1t

Gross profit Margin, %

74%66%69%
show all
Annual
JPYFY, 2018FY, 2019FY, 2020

Cash

294.5b702.1b637.6b

Accounts Receivable

369.7b661.0b715.2b

Inventories

212.9b986.7b759.6b

Current Assets

1.1t3.1t2.5t
Quarterly
JPYQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021

Cash

231.5b317.1b297.9b593.7b543.5b568.3b589.8b630.9b

Inventories

221.4b233.3b223.4b902.5b840.8b801.3b759.4b743.5b

Current Assets

1.0t1.1t2.7t2.9t2.4t2.5t2.5t2.6t

PP&E

528.2b533.1b601.8b1.5t1.5t1.5t1.4t1.4t
show all
Annual
JPYFY, 2018FY, 2019FY, 2020

Net Income

186.7b109.0b44.3b

Depreciation and Amortization

182.1b272.4b583.6b

Inventories

13.7b58.7b137.5b

Accounts Payable

6.9b(16.4b)(29.9b)
Quarterly
JPYQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021

Net Income

78.1b126.5b164.4b(20.6b)33.3b42.7b82.5b86.6b

Depreciation and Amortization

38.6b78.0b116.3b176.3b342.0b437.9b141.6b280.5b

Inventories

(12.5b)(21.5b)(15.4b)52.6b71.0b92.7b(4.4b)3.0b

Accounts Payable

(4.7b)(230.0m)(3.0b)(30.3b)(41.5b)(39.2b)(23.2b)(26.3b)
show all
JPYFY, 2018

EV/EBIT

3 x

EV/CFO

1.9 x

Revenue/Employee

65.0m

Debt/Equity

0.5 x

Debt/Assets

0.2 x

Financial Leverage

2 x

P/E Ratio

0.1
Show all financial metrics

Takeda Pharmaceutical Operating Metrics

Oct, 2018Feb, 2019May, 2019Jul, 2019Oct, 2019Feb, 2020May, 2020Jul, 2020Oct, 2020

Phase I Trials Products (Oncology)

5311

Phase I/II Trials Products (Oncology)

5443

Phase II Trials Products (Oncology)

79778

Phase III Trials Products (Oncology)

8910777765
Show all operating metrics

Takeda Pharmaceutical Acquisitions / Subsidiaries

Company NameDateDeal Size
PvP BiologicsFebruary 26, 2020$330 m
ShireApril 25, 2018$62 b
TiGenixJanuary 05, 2018€520 m
ARIAD PharmaceuticalsJanuary 09, 2017$5.2 b
InviragenMay 07, 2013
LigoCyte PharmaceuticalsOctober 05, 2012$60 m
IntellikineDecember 21, 2011$310 m
Nycomed PharmaMay 19, 2011€9.6 b
IDM Pharma , Inc.June 24, 2009
Millennium PharmaceuticalsFebruary 01, 2008$8.69 b
Show more

Takeda Pharmaceutical Revenue Breakdown

Embed Graph

Takeda Pharmaceutical revenue breakdown by business segment: 21.2% from Gastroenterology, 5.2% from Rare Metabolic, 10.2% from Rare Hematology, 12.0% from PDT Immunology, 12.8% from Oncology, 13.3% from Neuroscience and 25.4% from Other

Takeda Pharmaceutical revenue breakdown by geographic segment: 18.0% from Japan, 48.5% from United States, 19.6% from Europe and Canada, 5.0% from Asia (excluding Japan) and 8.9% from Other

Human Capital Metrics

Source: www.takeda.com, www.takeda.com, www.takeda.com
Embed Graph
Show all human capital metrics

Takeda Pharmaceutical Cybersecurity Score

Cybersecurity ratingPremium dataset

C

72/100

Learn more about our premium products
SecurityScorecard logo

Takeda Pharmaceutical Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

Learn more about our premium products
CSRHub logo

Takeda Pharmaceutical Online and Social Media Presence

Takeda Pharmaceutical's Trends

Embed Graph

Takeda Pharmaceutical Company Culture

  • Overall Culture

    A+

    79/100

  • CEO Rating

    A+

    82/100

  • Compensation

    A+

    81/100

  • Diversity

    A+

    79/100

Learn more on Comparably

Takeda Pharmaceutical News and Updates

December 15, 2020

U.S. Food and Drug Administration Accepts New Drug Application for Review, Grants Priority Review for Takeda’s TAK-721 (budesonide oral suspension) for the Treatment of Eosinophilic Esophagitis

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the United States (U.S.) Food and Drug Administration (FDA) has accepted for review the company’s New Drug Application (NDA) and granted Priority Review for the investigational therapy budesonide oral suspensio…
December 08, 2020

Takeda Announces Approval of TAKHZYRO® (lanadelumab) subcutaneous injection in China for the Treatment of Hereditary Angioedema

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that China’s National Medical Products Administration (NMPA) has approved TAKHZYRO® (lanadelumab) subcutaneous injection for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients 12 years and old…
December 07, 2020

Takeda Presents Real-World Evidence at ASH 2020, Demonstrating Its Long-Standing Commitment to Personalizing Treatments for Rare Bleeding Disorders

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”), today presented five hematology poster presentations and four abstracts at the 62nd American Society of Hematology (ASH) Annual Meeting & Exposition that underscore its commitment to advancing treatments for rare bleeding dis…
December 04, 2020

Y-mAbs and Takeda Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) and Omburtamab in Israel

Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB) (the “Company” or “Y-mAbs”) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer and Takeda Israel, a wholly owned subsidiary of Takeda Pharmace…
December 04, 2020

New Phase 3 Data Show TAK-620 (maribavir), an Investigational Drug for the Treatment of Transplant Recipients with Refractory/Resistant Cytomegalovirus (CMV) Infections, Meets Primary Endpoint

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced top-line results from the Phase 3 clinical trial evaluating the efficacy and safety of the investigational drug TAK-620 (maribavir), in the treatment of transplant recipients with refractory/resistant cytomegalovir…
December 02, 2020

Takeda Further Enables Hemophilia A Personalized Care With Launch of myPKFiT® Software for ADYNOVATE® [Antihemophilic Factor (Recombinant), PEGylated]

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the U.S. availability of myPKFiT® for ADYNOVATE® [Antihemophilic Factor (Recombinant), PEGylated], a web-based software and mobile application that is the first and only pharmacokinetic (PK)-dosing software approved…
Show more

 Takeda Pharmaceutical Frequently Asked Questions

  • When was Takeda Pharmaceutical founded?

    Takeda Pharmaceutical was founded in 1781.

  • Who are Takeda Pharmaceutical key executives?

    Takeda Pharmaceutical's key executives are Andrew S. Plump, Masato Iwasaki and Christophe Weber.

  • How many employees does Takeda Pharmaceutical have?

    Takeda Pharmaceutical has 47,495 employees.

  • What is Takeda Pharmaceutical revenue?

    Latest Takeda Pharmaceutical annual revenue is ¥3.3 t.

  • What is Takeda Pharmaceutical revenue per employee?

    Latest Takeda Pharmaceutical revenue per employee is ¥69.3 m.

  • Who are Takeda Pharmaceutical competitors?

    Competitors of Takeda Pharmaceutical include Nipro Corporation, Grifols and Codiak Biosciences.

  • Where is Takeda Pharmaceutical headquarters?

    Takeda Pharmaceutical headquarters is located at 1-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo.

  • Where are Takeda Pharmaceutical offices?

    Takeda Pharmaceutical has offices in Tokyo, Fujisawa, Fukuchiyama, Hikari and in 47 other locations.

  • How many offices does Takeda Pharmaceutical have?

    Takeda Pharmaceutical has 52 offices.